{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:19:37Z","timestamp":1778109577034,"version":"3.51.4"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pulmonary involvement is the most common leading cause of morbidity and mortality associated with systemic sclerosis. Therefore, identifying the various patterns of pul-monary affection is crucial in the clinical management of these patients. In the current study, we aim to investigate the patterns of interstitial lung disease (ILD) associated with SSc patients (SSc-ILD) and their relation to serologic markers and clinical parameters.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A cross-sectional study was undertaken on thirty-four adult SSc patients who met the 2013 ACR\/EULAR criteria for SSc and Forty healthy controls of matched age and sex. The patients were subjected to history taking, clinical examination, skin assessment using the modified Rodnan Skin Score (mRSS), chest x-ray (CXR), pulmonary function test (PFTs), and high resolution com-puted tomography of the chest (HRCT). Routine laboratory tests were conducted in addition to im-munologic tests and an enzyme-linked immunosorbent assay (ELISA) to determine the IL-33 level.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>ILD was found in 23 SSc patients (67.6%); 20 patients had diffuse type while 3 patients had limited type. Non-specific interstitial pneumonia (NSIP) was found in 56.5%, usual interstitial pneumonia (UIP) was found in 21.7%, pleuroparenchymal fibroelastosis (PPFE) was found in 8.7%, and organizing pneumonia (OP) with the mixed pattern was found in 13% of SSc patients. Additionally, the mean IL-33 level in SSc patients was 98\u00b112.7 compared to 66.2\u00b110.6 in the con-trol group (p &lt; 0.001), with ILD patients having a significantly higher level (101.7\u00b113.4) than those without (90.4\u00b16.2), and a strong positive correlation with mRSS.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Even in asymptomatic patients with SSc, ILD is prevalent, with NSIP being the most common pattern. IL-33 could be considered a potential biomarker for predicting the presence of ILD in SSc patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397118666220818095927","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T12:01:51Z","timestamp":1660910511000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic\nSclerosis: Relation to Disease Parameters"],"prefix":"10.2174","volume":"19","author":[{"given":"Abeer Ali","family":"Abdelati","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Alexandria\nUniversity, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram Abd-Elmonaem","family":"Deghady","sequence":"additional","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"Chest Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim Aly","family":"Bastawy","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"198","volume":"66","author":"Varga J.","year":"2008","unstructured":"Varga J.; Systemic sclerosis: An update. Bull NYU Hosp Jt Dis 2008,66(3),198-202","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"ref=2","first-page":"156","volume":"32","author":"Nihtyanova S.I.","year":"2014","unstructured":"Nihtyanova S.I.; Ong V.H.; Denton C.P.; Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014,32(2)(Suppl. 81),156-164","journal-title":"Clin Exp Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"iii40","DOI":"10.1093\/rheumatology\/kep109","volume":"48","author":"Wells A.U.","year":"2009","unstructured":"Wells A.U.; Steen V.; Valentini G.; Pulmonary complications: One of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009,48(Suppl. 3),iii40-iii44","journal-title":"Rheumatology (Oxford)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"Solomon J.J.","year":"2013","unstructured":"Solomon J.J.; Olson A.L.; Fischer A.; Bull T.; Brown K.K.; Raghu G.; Scleroderma lung disease. Eur Respir Rev 2013,22(127),6-19","journal-title":"Eur Respir Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0272-5231(05)70112-X","volume":"19","author":"Minai O.A.","year":"1998","unstructured":"Minai O.A.; Dweik R.A.; Arroliga A.C.; Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998,19(4),713-731","journal-title":"Clin Chest Med"},{"key":"ref=6","first-page":"22","volume":"14","author":"Gohari Moghadam K.","year":"2011","unstructured":"Gohari Moghadam K.; Gharibdoost F.; Parastandechehr G.; Salehian P.; Assessments of pulmonary involvement in patients with systemic sclerosis. Arch Iran Med 2011,14(1),22-26","journal-title":"Arch Iran Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/rheumatology\/ken271","volume":"47","author":"Wells A.U.","year":"2008","unstructured":"Wells A.U.; High resolution computed tomography and scleroderma lung disease. Heumatology (Oxford) 2008,47(5),v59-v61","journal-title":"Heumatology (Oxford)"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1571-5078(04)02010-0","author":"Goh N.S.","year":"2004","unstructured":"Goh N.S.; Bois R.M.; Interstitial disease in systemic sclerosis. Handbook of systemic autoimmune diseases 2004,181-207","journal-title":"Handbook of systemic autoimmune diseases"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0889-857X(05)70296-9","volume":"22","author":"White B.","year":"1996","unstructured":"White B.; Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996,22(4),695-708","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/08830189509056716","volume":"12","author":"Postlethwaite A.E.","year":"1995","unstructured":"Postlethwaite A.E.; Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995,12(2-4),247-258","journal-title":"Int Rev Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","volume":"3","author":"Moussion C.","year":"2008","unstructured":"Moussion C.; Ortega N.; Girard J.P.; The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel \u2018alarmin\u2019? PLoS One 2008,3(10),e3331","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JIM.0000000000000213","volume":"63","author":"Wei J.","year":"2015","unstructured":"Wei J.; Zhao J.; Schrott V.; Red blood cells store and release interleukin-33. J Investig Med 2015,63(6),806-810","journal-title":"J Investig Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cmi.2016.34","volume":"14","author":"Bertheloot D.","year":"2017","unstructured":"Bertheloot D.; Latz E.; HMGB1, IL-1&#x3B1; IL-33 and S100 proteins: Dual function alarmins. Cell Mol Immunol 2017,14(1),43-64","journal-title":"Cell Mol Immunol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","volume":"45","author":"Torok K.S.","year":"2015","unstructured":"Torok K.S.; Kurzinski K.; Kelsey C.; Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T helper cell associated cytokine profiles. Semin Arthritis Rheum 2015,45(3),284-293","journal-title":"Semin Arthritis Rheum"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"Hoogen F.","year":"2013","unstructured":"Hoogen F.; Khanna D.; Fransen J.; 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013,65(11),2737-2747","journal-title":"Arthritis Rheum"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"Khanna D.","year":"2017","unstructured":"Khanna D.; Furst D.E.; Clements P.J.; Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017,2(1),11-18","journal-title":"J Scleroderma Relat Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3346\/jkms.2011.26.9.1132","volume":"26","author":"Hong Y.S.","year":"2011","unstructured":"Hong Y.S.; Moon S.J.; Joo Y.B.; Measurement of interleukin-33 (IL-33) and IL-33 receptors (SST2 AND ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011,26(9),1132-1139","journal-title":"J Korean Med Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"Fischer A.","year":"2015","unstructured":"Fischer A.; Antoniou K.M.; Brown K.K.; Cadranel J.; Corte T.J.; du Bois R.M.; An official European Respiratory Society\/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015,46,976-987","journal-title":"Eur Respir J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1148\/radiol.2322031223","volume":"232","author":"Desai S.R.","year":"2004","unstructured":"Desai S.R.; Veeraraghavan S.; Hansell D.M.; CT features of lung disease in patients with systemic sclerosis: Comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004,232(2),560-567","journal-title":"Radiology"},{"key":"ref=20","author":"Kirkpatrick L.A.","year":"2013","unstructured":"Kirkpatrick L.A.; Feeney B.C.; A simple guide to IBM SPSS statistics for version 20.0. 2013"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"Tyndall A.J.","year":"2010","unstructured":"Tyndall A.J.; Bannert B.; Vonk M.; Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010,69(10),1809-1815","journal-title":"Ann Rheum Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1148\/radiographics.22.suppl_1.g02oc04s151","volume":"22","author":"Kim E.A.","year":"2002","unstructured":"Kim E.A.; Lee K.S.; Johkoh T.; Interstitial lung diseases associated with collagen vascular diseases: Radiologic and histopathologic findings. Radiographics 2002,22,S151-S165","journal-title":"Radiographics"},{"key":"ref=23","first-page":"519","volume":"64","author":"Russell S.","year":"2011","unstructured":"Russell S.; Marie H.; Ernest L.; Murray B.; Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2011,64(4),519-524","journal-title":"Arthritis Care Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejr.2017.06.004","volume":"40","author":"Hafez E.A.","year":"2018","unstructured":"Hafez E.A.; Hamza S.H.; Morad C.S.; Abd Alkader A.A.; Pulmonary manifestations in Egyptian patients with systemic sclerosis. Egypt Rheumatol 2018,40(1),39-44","journal-title":"Egypt Rheumatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1183\/13993003","volume":"56","author":"Mohamad N.","year":"2020","unstructured":"Mohamad N.; Sophie L.; Loic B.; Salim S.M.; Fabienne B.; S&#xE9;bastien M.; Prevalence and mortality of systemic sclerosis-associated interstitial lung disease (SSc-ILD) using the French national health insurance system (SNDS) database in France. Eur Respir J 2020,56,805","journal-title":"Eur Respir J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/01.rti.0000213572.16904.40","volume":"22","author":"Shah R.M.","year":"2007","unstructured":"Shah R.M.; Jimenez S.; Wechsler R.; Significance of ground-glass opacity on HRCT in long-term follow up of patients with systemic sclerosis. J Thorac Imaging 2007,22(2),120-124","journal-title":"J Thorac Imaging"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/BOR.0000000000000323","volume":"28","author":"Molberg &#xD8;.","year":"2016","unstructured":"Molberg &#xD8;.; Hoffmann A.M.; Interstitial lung disease in systemic sclerosis: Progress in screening and early diagnosis. Curr Opin Rheumatol 2016,28(6),613-618","journal-title":"Curr Opin Rheumatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/art.40441","volume":"70","author":"Bernstein E.J.","year":"2018","unstructured":"Bernstein E.J.; Khanna D.; Lederer D.J.; Screening high resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: A global survey of rheumatologists. Arthritis Rheumatol 2018,70(6),971-972","journal-title":"Arthritis Rheumatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"Travis W.D.","year":"2013","unstructured":"Travis W.D.; Costabel U.; Hansell D.M.; An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013,188(6),733-748","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e0180283","DOI":"10.1371\/journal.pone.0180283","volume":"12","author":"Enomoto Y.","year":"2017","unstructured":"Enomoto Y.; Nakamura Y.; Colby T.V.; Radiologic pleuroparenchymal fibroelastosis like lesion in connective tissue disease related interstitial lung disease. PLoS One 2017,12(6),e0180283","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.resinv.2012.06.003","volume":"50","author":"Watanabe K.","year":"2012","unstructured":"Watanabe K.; Nagata N.; Kitasato Y.; Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis. Respir Investig 2012,50(3),88-97","journal-title":"Respir Investig"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/01.rhu.0000083860.27509.f1","volume":"9","author":"Taylor J.G.","year":"2003","unstructured":"Taylor J.G.; Bolster M.B.; Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol 2003,9(4),239-245","journal-title":"J Clin Rheumatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","volume":"30","author":"Yanaba K.","year":"2011","unstructured":"Yanaba K.; Yoshizaki A.; Asano Y.; Kadono T.; Sato S.; Serum IL-33 levels are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011,30(6),825-830","journal-title":"Clin Rheumatol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3389\/fimmu.2018.02663","volume":"9","author":"Li L.","year":"2018","unstructured":"Li L.; Zhu H.; Zuo X.; Interleukin-33 in systemic sclerosis: Expression and pathogenesis. Front Immunol 2018,9,2663","journal-title":"Front Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/1573397117666210913102759","volume":"18","author":"Groseanu L.","year":"2022","unstructured":"Groseanu L.; Petrescu S.; Balanescu A.; Do we have good activity indices in systemic sclerosis? Curr Rheumatol Rev 2022,18(1),39-47","journal-title":"Curr Rheumatol Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","volume":"34","author":"Vettori S.","year":"2014","unstructured":"Vettori S.; Cuomo G.; Iudici M.; Early systemic sclerosis: Serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 2014,34(6),663-668","journal-title":"J Clin Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1074\/jbc.M111.298703","volume":"287","author":"Kakkar R.","year":"2012","unstructured":"Kakkar R.; Hei H.; Dobner S.; Lee R.T.; Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012,287(9),6941-6948","journal-title":"J Biol Chem"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220818095927","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207623\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397118666220818095927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:53:06Z","timestamp":1685015586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207623\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397118666220818095927","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}